Tyrolpath, the largest private pathology laboratory in western Austria, has become the first lab in Austria to adopt MSK‑IMPACT‑Flex powered with SOPHiA DDM, a move described by SOPHiA GENETICS as a major milestone for precision oncology in the country.
The decision comes against a backdrop of roughly 45,000 new cancer diagnoses in Austria each year, underscoring the urgent demand for comprehensive genomic profiling (CGP) to uncover actionable mutations.
MSK‑IMPACT‑Flex is built on the proven framework of the original MSK-IMPACT test, now enhanced by the cloud‑native SOPHiA DDM platform. This combination enables laboratories to conduct flexible, cost‑efficient, end‑to‑end analysis of solid tumour biomarkers—covering DNA and RNA biomarkers, complex signatures, and structural changes in tumour genomes.
With this adoption, Tyrolpath will be able to offer advanced molecular profiling within Austria, potentially reducing the need for outsourcing tests abroad and enabling more rapid, locally managed diagnostics and treatment planning. According to SOPHiA GENETICS, this could significantly strengthen the country’s capacity for precision oncology.
The implementation of MSK‑IMPACT‑Flex at Tyrolpath represents an important step in bringing globally validated genomic profiling tools—originally developed by Memorial Sloan Kettering Cancer Center—to Austrian patients. The single‑workflow, streamlined solution may accelerate diagnostic turnaround times and allow more comprehensive tumour characterization from a single assay.
By adopting this advanced CGP solution, Tyrolpath signals a growing shift across Europe toward integrating state‑of‑the‑art genomic diagnostics into routine oncology care, enhancing the potential for tailored cancer therapies based on each patient’s tumour profile.
Also Read